Top vaccine researchers have asked the government to step in and take on the indemnity risk for an international clinical trial that aims to determine the efficacy of Moderna’s mRNA coronavirus vaccine against strains circulating in Africa, as well as in people living with HIV.

A $130m (R1.77bn) trial funded by the US National Institutes of Health is ready to launch in eight African countries, including SA, but has stalled because the two companies that manufacture mRNA vaccines, Moderna and Pfizer, are unwilling to provide their shots, according to a report published in Science Magazine at the weekend...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now